There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aptose Biosciences (APTO – Research Report) and CureVac (CVAC – Research Report) with bullish sentiments.
Aptose Biosciences (APTO)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Aptose Biosciences today and set a price target of $12.00. The company’s shares closed last Monday at $0.73.
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Aptose Biosciences is a Strong Buy with an average price target of $7.33.
See the top stocks recommended by analysts >>
CureVac (CVAC)
JMP Securities analyst Roy Buchanan reiterated a Buy rating on CureVac today and set a price target of $34.00. The company’s shares closed last Monday at $12.24.
According to TipRanks.com, Buchanan is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CureVac with a $19.17 average price target, a 59.8% upside from current levels. In a report issued on January 19, UBS also upgraded the stock to Buy with a $18.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on APTO:
- Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
- Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- Aptose Biosciences Establishes New At-The-Market Facility
- Aptose Biosciences establishes at-the-market facility
